These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 29459379)

  • 1. OxyContin maker stops marketing opioids, as report details payments to advocacy groups.
    Dyer O
    BMJ; 2018 Feb; 360():k791. PubMed ID: 29459379
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OxyContin in Ontario: the multiple materialities of prescription painkillers.
    King S
    Int J Drug Policy; 2014 May; 25(3):486-93. PubMed ID: 24612641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Illicit use of opioids: is OxyContin a "gateway drug"?
    Grau LE; Dasgupta N; Harvey AP; Irwin K; Givens A; Kinzly ML; Heimer R
    Am J Addict; 2007; 16(3):166-73. PubMed ID: 17612819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study of OxyContin use among individuals with substance use disorders.
    Levy MS
    J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J; Kohler JC
    Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-medical use of OxyContin Tablets in the United States.
    Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
    J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose controlled-release oxycodone in hospice care.
    Bercovitch M; Adunsky A
    J Pain Palliat Care Pharmacother; 2006; 20(4):33-9. PubMed ID: 17182504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The patient-consumer-advocate nexus: the marketing and dissemination of gardasil, the human papillomavirus vaccine, in the United States.
    Gottlieb SD
    Med Anthropol Q; 2013 Sep; 27(3):330-47. PubMed ID: 24248992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "We Are Not Really Marketing Mental Health": Mental Health Advocacy in Zimbabwe.
    Hendler R; Kidia K; Machando D; Crooks M; Mangezi W; Abas M; Katz C; Thornicroft G; Semrau M; Jack H
    PLoS One; 2016; 11(9):e0161860. PubMed ID: 27607240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OxyContin crisis: problematisation and responsibilisation strategies in addiction, pain, and general medicine journals.
    Whelan E; Asbridge M
    Int J Drug Policy; 2013 Sep; 24(5):402-11. PubMed ID: 23452867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing practices amid the OxyContin crisis: examining the effect of print media coverage on opioid prescribing among physicians.
    Borwein A; Kephart G; Whelan E; Asbridge M
    J Pain; 2013 Dec; 14(12):1686-1693.e1. PubMed ID: 24290448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OxyContin and neonatal abstinence syndrome.
    Rao R; Desai NS
    J Perinatol; 2002 Jun; 22(4):324-5. PubMed ID: 12032797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.